GlassScriptPhysician profile
Tamara Gorman
NPI 1154953099
$16,208.82
in general payments reported to CMS, 2019-2025
42 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,456 · 2022: $4,360 · 2023: $3,389 · 2024: $3,694 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,419 · Travel and Lodging: $955 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,419.06 |
| Travel and Lodging | $954.52 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $1,968.82 | 2021-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $1,818.78 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,535.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,050.29 | 2021-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $1,003.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $996.97 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $756.29 | 2021-2022 | |
| Dexcom, INC. | $681.20 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Alexion Pharmaceuticals, INC. | $616.42 | 2022-2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $598.57 | 2021-2025 | |
| Medtronic, INC. | $442.82 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $425.10 | 2021-2024 | Nexletol |
| Abbott Laboratories | $392.86 | 2022-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.44 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $392.39 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $372.96 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $310.47 | 2021-2024 | |
| Recordati_rare_diseases_inc. | $300.40 | 2021-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $279.76 | 2022-2025 | Tymlos |
| Mannkind Corporation | $266.50 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $228.21 | 2021-2024 | |
| Ucb, INC. | $184.82 | 2025 | Bimzelx |
| Antares Pharma, INC. | $164.91 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $152.48 | 2021-2022 | |
| Cequr Corporation | $111.34 | 2023-2024 | Cequr Simplicity |
| Lifescan, INC. | $102.99 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $90.73 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $69.47 | 2021-2022 | |
| Kyowa Kirin, INC. | $65.29 | 2023-2025 | |
| Ibsa Pharma INC. | $63.81 | 2022-2023 | Tirosint, Licart |
| Sequel Med Tech, LLC | $62.49 | 2025 | Twiist |
| Currax Pharmaceuticals LLC | $53.50 | 2022 | |
| Eusa Pharma (US) LLC | $46.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $37.38 | 2021 | |
| Beta Bionics, INC. | $33.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Zealand Pharma US, INC. | $29.06 | 2021 | |
| Halozyme INC | $27.86 | 2023 | |
| Endo Pharmaceuticals INC. | $19.31 | 2022 | |
| Astellas Pharma US INC | $17.09 | 2023 | Veozah |
| Neurocrine Biosciences, INC. | $17.06 | 2024 | |
| Horizon Therapeutics Plc | $14.51 | 2022 | |
| Amryt Pharma Holdings LTD | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Gorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.